Reduction of visual P300 during transient global amnesia. Electroencephalogr Clin Neurophysiol 1994;92:422-5 Transient global amnesia (TGA) is a syndrome of selective loss of recent memory without other neurological deficits. Auditory and visual P300s were recorded during and after TGA to investigate the contribution of the short-term memory system to P300 generation. The auditory P300 during TGA was comparable to that recorded I week and 9 months after TGA. In contrast to the auditory modality, the visual target P300 was reduced in amplitude during TGA and at I week after the attack. The P300 to novel visual stimuli was also reduced during TGA. Both target and novelty visual P300 recovered by 9 months after TGA. The results support the notion that the neuronal networks responsible for P300 generation are modality dependent and that brain structures perfused by the posterior circulation are involved in visual P300 generation.
The localized PET cerebral correlates of the painful experience in the normal human brain have previously been demonstrated. This study examined whether these responses are different in patients with chronic atypical facial pain. The regional cerebral responses to non-painful and painful thermal stimuli in six female patients with atypical facial pain and six matched female controls were studied by taking serial measurements of regional blood flow by PET. Both groups displayed highly significant differences in responses to painful heat compared with non-painful heat in the thalamus, anterior cingulate cortex (area 24), lentiform nucleus, insula, and prefrontal cortex. These structures are closely related to the "medial pain system". The atypical facial pain group had increased blood flow in the anterior cingulate cortex and decreased blood flow in the prefrontal cortex. These findings show the importance of the anterior cingulate cortex and the reciprocal (possibly inhibitory) connections with the prefrontal cortex in the processing of pain in patients with this disorder. A hypothesis is proposed to explain the mechanisms of cognitive and pharmacological manipulation of these pain processes.
Diener HC. A review of current treatments for migraine. Eur Neurol 1994; 34 Suppl 2:18-25 Acute drug therapy is the mainstay of treatment for migraine sufferers, with prophylaxis reserved for those with frequent or severe attacks. The majority of treatments have been in use for many years, although their value is often poorly documented due to a lack of well-controlled trials undertaken with defined diagnostic criteria and study end-points. Analgesics with anti-emetics, nonsteroidal anti-inflammatory drugs and ergot derivatives are used for acute treatment. Recently, the selective 5HT 1 receptor agonist sumatriptan has become available and been shown to have significant benefits over traditional therapies for the acute treatment of migraine. Beta-blockers, flunarizine and 5HT 2 antagonists have been used for prophylaxis, and although many patients report a reduction in attack frequency, breakthrough attacks still occur.
Edmeads J. The diagnosis and treatment of migraine: a clinician's view. Eur Neurol 1994; 34 Suppl 2:2-5 The introduction of the International Headache Society (IHS) diagnostic criteria has made migraine a "positive" diagnosis, not one of exclusion. Studies in Canada have shown that many sufferers do not consult their physician about their migraine, and that the use of over-the-counter and prescription analgesics is common. Treatment should comprise a physician-patient partnership based on a correct and accepted diagnosis, in which both participate in a programme of education about the condition, identification and reduction of migraine triggers, and appropriate use of non-pharmacological, prophylactic and acute pharmacological treatments. The pathogenesis of chronic daily headache is uncertain, but it is frequently associated with habitual overuse of simple analgesics and ergotamines.
Eschalier A, Mestre C, Dubray C, Ardid D. Why are antidepressants effective as pain relief?. CNS Drugs 1994; 2:261-7 Results from experimental and clinical studies indicate that antidepressants have specific analgesic properties in chronic pain. The exact site of action of these drugs (spinal or supraspinal) has yet to be established. The most likely mechanism of action of antidepressants in pain relief is via effects on monoaminergic and opioidergic systems. The most frequently postulated mechanism of action is an effect on serotonergic mechanisms; however, data are equivocal. Some data suggest that antidepressants that inhibit both serotonin (5-hydroxytryptamine; 5HT) and noradrenaline (norepinephrine) reuptake are the most effective agents in relieving pain, suggesting that there may be some noradrenergic involvement. The analgesic effects of antidepressants are reversed by the opioid antagonist naloxone, and changes in opioid levels are induced by these compounds. Therefore, antidepressants may also act via the opioid system. Nevertheless, direct binding of antidepressants to opioid receptors seems unlikely. Other less validated hypotheses have also been proposed. Further clinical and experimental studies are needed to better elucidate the mechanism of action of antidepressants in pain relief.
Goadsby PJ. The clinical profile of sumatriptan: cluster headache. Eur Neurol 1994; 34 Suppl 2:35-9 Cluster headache is a rare form of severe idiopathic headache characterized by unilateral short-lasting episodes of excruciating pain in association with autonomic disturbances. Subcutaneous sumatriptan has been investigated as an acute treatment for cluster headache in two randomized, double-blind, placebo-controlled, crossover trials. About 75% of patients given subcutaneous sumatriptan 6 mg reported headache relief within 15 min, in comparison with 26-35% given placebo (p < 0.001 in both studies). The need for rescue medication (100% oxygen by inhalation) at 15 min was significantly lower after sumatriptan treatment, as were the severity of functional disability and incidence of non-headache symptoms. Results of a long-term study indicate that the tolerability and efficacy of sumatriptan 6 mg is maintained in long-term use, and that there is no evidence of tachyphylaxis. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994;344:985 -6 Three to five percent of patients taking the 5HT (1D) agonist sumatriptan for migraine have chest discomfort, suggesting a cardiac origin. We have investigated an alternative explanation of an oesophageal cause in 24 volunteers after the subcutaneous administration of a supratherapeutic dose of sumatriptan (16 mg) or placebo in a randomized, double-blind crossover study. Sumatriptan did not alter the electrocardiogram but increased the amplitude (p < 0.001) and duration (p < 0.001) of oesophageal contractions without affecting velocity of propagation. Clinically abnormal motility was also increased (p = 0.001), and was more common in the five subjects with chest pain after sumatriptan. The effect of sumatriptan on oesophageal function provides an alternative explanation for the chest symptoms. Genetic isolates are highly useful in analyses of the molecular background of complex diseases, since the enrichment of a limited number of predisposing genes can be predicted in representative families or in specific geographical regions. It has been suggested that the pathophysiology and etiology of familial hemiplegic migraine (FHM) and typical migraine with aura are most probably the same. Recent assignment of FHM locus to chromosome 19p in two French families makes it now possible to test this hypothesis. We report here linkage data on four families with multiple cases of migraine disorder originating from the genetically isolated population of Finland. We were interested to discover whether the migraine in these families would also show linkage to the markers on 19p. We could exclude a region of 50 cM, flanking the reported FHM locus, as a site of migraine locus in our four families. It seems evident that locus heterogeneity exists between different diagnostic classes of migraine spectrum of diseases and also between different ethnic groups.
Hu XH, Tang HW, Li QS, Huang XF. Central mechanism of indomethacin analgesia. Eur J Pharmacol 1994; 263:53-7 The analgesic effect of indomethacin was investigated by using the visceral pain model in rabbits. After intravenous administration of indomethacin (2 mg/kg), the maximum increase of the visceral pain threshold was 0.42 ± 0.31 mA (p < 0.05). The analgesic effect lasted 40 min. After intraventricular microinjection of indomethacin (50 mg), the maximum increase of the visceral pain threshold was 0.37 ± 0.43 mA. After intravenous administration of indomethacin, the content of norepinephrine in perfusates of rabbit fourth ventricle was significantly increased from 115.10 ± 8.05 to 32.16±6.15 mg/40 ml (p < 0.05), compared with data for the control group. The content of beta-endorphin in the perfusate after indomethacin administration was decreased from 5 to 25 min and slightly increased from 25 to 35 min, compared with the data for the control group, but there was no significant difference (p > 0.05). Furthermore, intraventricular microinjection of phentolamine (50 mg) could block the analgesic effect of an intravenous injection of indomethacin, while naloxone could not. The results imply that prostaglandins of the central nervous system could induce hyperalgesia. Indomethacin injected centrally and peripherally has an analgesic effect on visceral pain. This analgesic effect is mediated by alpha-adrenoceptors. Beta-endorphin does not participate in the analgesic action of indomethacin.
Jensen R, Fuglsangfrederiksen A, Olesen J. Quantitative surface EMG of pericranial muscles in headache. A population study. Electroencephalogr Clin Neurophysiol 1994; 93:335-44 Quantitative EMG from the right frontal and both temporal muscles was studied in 547 adults randomly selected from the general population. The study was part of a multifaceted, epidemiological study of different headache disorders. Surface EMG was recorded by an observer blinded to the persons' history of headache, previous illness and mental state. The present study provides data on amplitude and mean and median frequency levels in migraine and tension-type headache. Chronic headache sufferers had higher amplitude values at rest in their temporal muscles than migraineurs, subjects with episodic tension-type headache and subjects without any experience of headache, probably due to insufficient relaxation. Frequency values during maximal voluntary contraction were decreased in chronic headache subjects and decreased with increasing frequency of headache in the previous year, indicating that chronic fatigue and/or changed fiber type composition exist in frequent headache sufferers. During experimental cold and pain stimulation no significant differences between headache subjects and the rest of the population were detected. Only subjects without any experience of headache had increased amplitude values during pain stimulation. No significant relation of amplitude values to frequency of tension-type headache or migraine in the previous year was detected. In 66 subjects with actual headache amplitude values were increased in the frontal muscle during rest, indicating increased tension. Moreover, amplitude values were decreased in both the temporal and the frontal muscles during maximal voluntary contraction, indicating submaximal contraction during pain. The present study supports the importance of peripheral factors such as increased fatigability, morphological, and/or metabolic changes in the pathogenesis of tension-type headache. However, the diagnostic value of EMG in migraine and tension-type headache is limited.
Jørgensen HS, Jespersen HF, Nakayama H, Raaschou HO, Olsen TS. Headache in stroke: the Copenhagen Stroke Study. Neurology 1994; 44:1793-7 Background: Many aspects of stroke-related headache, such as its incidence, pathophysiology, risk factors, and relation to stroke severity and outcome, are uncertain. Design: A prospective, community-based study including 1, 128 consecutive acute stroke patients; 867 (77%) were able to communicate. Stroke severity and the clinical course were assessed using the Scandinavian Stroke Scale (SSS). CT was performed in 84% of patients. In the data analysis, multivariate regression analyses were used when appropriate. Results: Two hundred and forty-one (28%) of the 867 patients had headache in relation to stroke onset. Independent risk factors were age (odds ratio [OR] per 20 years, 0.57; 95% confidence interval [CI], 0.43 to 0.86; p = 0.0001), female sex (OR, 1.6; CI, 1.2 to 2.2; p = 0.003), intracerebral hemorrhage (OR, 2.8; CI, 1.5 to 5.4; p = 0.002), stroke in the vertebrobasilar territory (OR, 1.7; CI, 1.1 to 2.3; p = 0.02), and ischemic heart disease (OR, 1.5; C1, 1.1 to 2.2; p = 0.01). In those patients in whom headache was lateralized (46%), it was ipsilateral to the lesion in 68% of cases (p = 0.01). There was no correlation between headache and (1) initial stroke severity as measured with the SSS (p = 0.75), (2) lesion size (p = 0.77), (3) whether or not CT showed cortical involvement (p = 0.29), (4) stroke outcome as measured with the SSS (p = 0.9), or (5) mortality (p = 0.75). Conclusion: Stroke-related headache is associated with factors such as age and sex. In patients capable of providing reliable headache information, headache is more frequent in strokes confined to the vertebrobasilar than to the carotid territory and is not associated with stroke severity or whether or not the cortex was involved. Stroke-related headache is not related to stroke outcome.
Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34 Suppl 2:6-11 To obtain accurate estimates of migraine prevalence, population-based studies are required. Clinic-based studies include a highly selected group of migraine sufferers. Even in population-based studies, there have been wide variations in estimates of migraine prevalence. A meta-analysis has shown that age, gender and case definition account for 70% of this variance. Recent studies using International Headache Society (IHS) diagnostic criteria have given relatively consistent estimates of migraine prevalence (about 15-18% of women and 6% of men) and indicate that migraine occurs most commonly in men and women aged 25-55 years. Migraine is a heterogeneous condition with a spectrum of severity and associated disability, and it is under-diagnosed worldwide.
Lloyd, K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994; 34 Suppl 2:40-3 The safety and tolerability of sumatriptan have been extensively studied. The majority of adverse events (defined as any medical event irrespective of possible causal relationship to treatment) were mild to moderate in intensity, transient and resolved spontaneously. In short-term studies, the most frequently reported adverse events were nausea, vomiting, dizziness, vertigo, malaise, fatigue, injection-site reactions, heaviness, pressure, feelings of warmth and headache. The adverse event profile was unchanged during long-term open treatment and was unaffected by frequency of treatment with sumatriptan. In 3-5% of patients, the symptoms of pressure and warmth were experienced in the chest, but extensive investigations, including ECG monitoring, have indicated that these symptoms are not normally associated with cardiac dysfunction.
Lord SM, Barnsley L, Wallis BJ, Bogduk N. Third occipital nerve headache: a prevalence study. J Neurol Neurosurg Psychiatry 1994; 57:1187-90 A consecutive series of 100 patients was studied to determine the prevalence of third occipital nerve headache in patients with chronic neck pain (> three months in duration) after whiplash. Seventy-one patients complained of headache associated with their neck pain. Headache was the dominant complaint of 40 patients, but was only a secondary problem for the other 31. Each patient with headache underwent double-blind, controlled diagnostic blocks of the third occipital nerve. On two separate occasions the nerve was blocked with either lignocaine or bupivacaine, in random order. The diagnosis of third occipital nerve headache was made only if both blocks completely relieved the patient's upper neck pain and headache and the relief lasted longer with bupivacaine. The prevalence of third occipital nerve headache among all 100 whiplash patients was 27% (95% confidence interval (95% CI) 18-36%) and among those with dominant headache the prevalence was as high as 53% (95% CI 37-68%). There were no distinguishing features on history or examination that enabled a definitive diagnosis to be made before the nerve blocks.
Those patients with a positive diagnosis, however, were significantly more likely to be tender over the C2-3 zygapophysial joint (p = 0.01). Third occipital nerve headache is a common condition in patients with chronic neck pain and headache after whiplash. Third occipital nerve blocks are essential to make this diagnosis.
McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59:9-43 Non-steroidal anti-inflammatory drugs have a direct action on spinal nociceptive processing in vivo with a relative order of potency which correlates with their capacity as inhibitors of cyclooxygenase activity. However, recent clinical surveys and new in vivo evidence strongly suggest that for some of these agents, centrally mediated analgesia may also be achieved by additional mechanisms, which are independent of prostaglandin synthesis inhibition. In this review we explore the likelihood for such mechanisms following an extensive survey of existing data. The implications of these mechanisms are discussed in the light of our current understanding of spinal nociceptive processing.
Pilgrim AJ. The clinical profile of sumatriptan: efficacy in migraine. Eur Neuro] 1994;34 Suppl 2:26-34
The efficacy of the 5HT 1 receptor agonist sumatriptan in the acute treatment of migraine has been investigated in an extensive programme of controlled clinical trials. Sumatriptan provided rapid relief from migraine headache with onset of relief occurring within 10 min of a 6 mg subcutaneous injection and within 30 min of a 100 mg oral dose. Maximum benefit was observed by 2 h after the injection and 4 h after the oral dose. Sumatriptan also significantly decreased the incidence of associated migraine symptoms (nausea, photophobia, phonophobia) and the need for rescue medication. Sumatriptan was an effective treatment for migraine with and without aura and when used at any time during the attack. Oral sumatriptan 100 mg provided significantly greater pain relief and had a more rapid onset of action than two commonly used acute treatments for migraine. Efficacy is maintained in long-term use, with no evidence of tachyphylaxis or dependence. Sumatriptan, whether given subcutaneously or orally, is an effective long-term acute treatment for migraine.
Steiger MJ, Farrah T, Rolles K, Harvey P, Burroughs AK. Cyclosporin associated headache. J Neurol Neurosurg Psychiatry 1994 -57:1258 Despite successful orthoptic liver transplantation some patients develop a recurrent headache that interferes with their quality of life. To estimate the frequency of this symptom 34 patients who had undergone orthoptic liver transplantation were questioned about the history and character of any headache. Six patients described a recurrent headache typical of migraine only since transplantation. In two patients the pain improved after reduction of cyclosporin dosage and thereby plasma cyclosporin concentration.
Stewart WF, Lipton RB. The economic and social impact of migraine. Eur Neurol 1994; 34 Suppl 2:12-17 
